These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32251153)

  • 1. Combination Therapy With Chemotherapy, Donor Lymphocyte Infusion With Concurrent Blinatumomab in Relapsed/Refractory Acute Precursor B-Lymphoblastic Leukemia.
    Choi HJ; Choi JY; Kim BK; An HY; Hong KT; Shin HY; Kang HJ
    J Pediatr Hematol Oncol; 2021 Mar; 43(2):e280-e283. PubMed ID: 32251153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
    Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
    Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.
    Contreras CF; Higham CS; Behnert A; Kim K; Stieglitz E; Tasian SK
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28718. PubMed ID: 33098744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia.
    Dombret H; Topp MS; Schuh AC; Wei AH; Durrant S; Bacon CL; Tran Q; Zimmerman Z; Kantarjian H
    Leuk Lymphoma; 2019 Sep; 60(9):2214-2222. PubMed ID: 30947585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
    Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
    Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
    Schlegel P; Lang P; Zugmaier G; Ebinger M; Kreyenberg H; Witte KE; Feucht J; Pfeiffer M; Teltschik HM; Kyzirakos C; Feuchtinger T; Handgretinger R
    Haematologica; 2014 Jul; 99(7):1212-9. PubMed ID: 24727818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
    Zugmaier G; Gökbuget N; Klinger M; Viardot A; Stelljes M; Neumann S; Horst HA; Marks R; Faul C; Diedrich H; Reichle A; Brüggemann M; Holland C; Schmidt M; Einsele H; Bargou RC; Topp MS
    Blood; 2015 Dec; 126(24):2578-84. PubMed ID: 26480933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of blinatumomab: a real world data.
    Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M
    Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group.
    Saito T; Hatta Y; Hayakawa F; Takahashi T; Hagihara M; Iida H; Minauchi K; Yamazaki E; Sugiura I; Murayama T; Sakura T; Mori N; Imai K; Yahagi Y; Atsuta Y; Saito AM; Hirakawa A; Kiyoi H; Matsumura I; Miyazaki Y;
    Int J Hematol; 2021 Mar; 113(3):395-403. PubMed ID: 33230647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific antibodies in acute lymphoblastic leukemia therapy.
    Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
    Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Queudeville M; Schlegel P; Heinz AT; Lenz T; Döring M; Holzer U; Hartmann U; Kreyenberg H; von Stackelberg A; Schrappe M; Zugmaier G; Feuchtinger T; Lang P; Handgretinger R; Ebinger M
    Eur J Haematol; 2021 Apr; 106(4):473-483. PubMed ID: 33320384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
    Ribera JM
    Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant.
    Ueda M; de Lima M; Caimi P; Tomlinson B; Little J; Creger R; Lazarus H; Cooper B
    Bone Marrow Transplant; 2016 Sep; 51(9):1253-5. PubMed ID: 27088374
    [No Abstract]   [Full Text] [Related]  

  • 14. Sequential Therapy of Inotuzumab Ozogamicin and Blinatumomab as a Bridge-to Hematopoietic Stem Cell Transplantation in a Pediatric Patient With Primary Refractory Acute Lymphoblastic Leukemia: A Case Report.
    Uchida E; Kurata T; Komori K; Kobayashi J; Kubota N; Sakashita K
    J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1228-e1230. PubMed ID: 34001796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.
    Kantarjian HM; Stein AS; Bargou RC; Grande Garcia C; Larson RA; Stelljes M; Gökbuget N; Zugmaier G; Benjamin JE; Zhang A; Jia C; Topp MS
    Cancer; 2016 Jul; 122(14):2178-85. PubMed ID: 27143254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
    Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Gibson A; Nunez C; Robusto L; Kammerer B; Garcia M; Roth M; Sheth R; Tewari P; Hittle A; Toepfer L; Torres R; Short NJ; Jabbour E; Jain N; Cuglievan B; McCall D
    Haematologica; 2024 Sep; 109(9):3042-3047. PubMed ID: 38779719
    [No Abstract]   [Full Text] [Related]  

  • 18. Refractory acute lymphoblastic leukemia in Chinese children: bridging to stem cell transplantation with clofarabine, cyclophosphamide and etoposide.
    Liu AP; Lee V; Li CK; Ha SY; Chiang AK
    Ann Hematol; 2016 Feb; 95(3):501-7. PubMed ID: 26666536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
    Stein AS; Kantarjian H; Gökbuget N; Bargou R; Litzow MR; Rambaldi A; Ribera JM; Zhang A; Zimmerman Z; Zugmaier G; Topp MS
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1498-1504. PubMed ID: 31002989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clofarabine-based salvage chemotherapy for relapsed or refractory acute leukemia before allogeneic stem cell transplantation: results from a case series.
    Grigoleit GU; Kapp M; Tan SM; Unzicker C; Einsele H; Mielke S; Topp MS; Stuhler G
    Leuk Lymphoma; 2009 Dec; 50(12):2071-4. PubMed ID: 19886845
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.